The Valens Company Expands Domestic Reach With Yukon Territory Distribution Agreement | New

Valens can now ship products to five provinces and one territory in Canada

KELOWNA, British Columbia, April 21, 2021 / PRNewswire / – Valens Inc. (TSX: VLNS) (OTCQX: VLNCF) (on “Company,” “The Valens company” or “Valens”), a leading manufacturer of cannabis products, today announced its entry into the Yukon market with an agreement to buy and sell cannabis with the Yukon Liquor Corporation (YLC).

The agreement allows the sale and distribution of products manufactured by Valens to authorized cannabis retailers in Yukon and on Cannabis Yukon, The e-commerce platform of the Yukon Liquor Corporation. Valens plans to bring a range of Cannabis 2.0 and 3.0 products to the Yukon market, which could include vapors, concentrates, beverages, topicals and edibles, expanding the variety of innovative formats available in the territory.

“Our entry into the Yukon market not only reinforces our ability to gain market share Canada, but also widens the selection and quality of products that consumers in the territory can access, ”said Tyler robson, CEO, co-founder and chairman of The Valens Company. “We have made significant progress in growing our cannabis distribution network and plan to increase our national position in the near term as we continue discussions with other private and government regulated retailers across the country.”

Products manufactured by Valens will be shipped to Yukon and available to consumers in the coming quarters.

At Valens, it’s personal.

About the company Valens

The Valens Company is a leading manufacturer of cannabis products with a mission to bring the benefits of cannabis to the world. The company provides exclusive cannabis processing services in five core technologies, in addition to product development, formulation and manufacture of premium packaged consumer products. The high-quality products of the company Valens are exclusively formulated for the medical, therapeutic, health and wellness and leisure consumer segments, and are offered in numerous product formats, including oils, vapors, concentrates, edibles and topicals, as well as pre-rolls. , with a focus on new generation product development and innovation. Its revolutionary patented emulsification technology, SōRSE ™ from Valens, converts cannabis oil into water-soluble emulsions for seamless integration into a variety of product formats, allowing near perfect dosage, stability and taste. In partnership with brand houses, consumer packaged goods companies and licensed cannabis producers around the world, the company continues to develop its diverse product portfolio in response to changing market preferences of cannabis consumers. keys. Through its wholly owned subsidiary Valens Labs Ltd., the company sets the standard for cannabis testing and research and development with From Canada The only ISO17025 accredited analytical services laboratory, named a Center of Excellence in Plant Sciences by partner and global scientific leader Thermo Fisher Scientific. Learn more about The Valens Company and its subsidiaries at

Notice Regarding Forward-Looking Statements

All information included in this press release, including any information on future financial or operational performance and other statements by The Valens Company that express management’s expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking or forward-looking information. – forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management’s current expectations and plans for the future. Whenever possible, words such as “plans”, “expects”, “planned”, “trends”, “forecasts”, “future”, “indications”, “potential”, “estimates”, ” predicts “,” anticipates “,” establish “,” believe “,” intend “,” ability to “, or statements that certain actions, events or results” may “,” should “,” might “,” would like “,” could “,” will “, or are” likely “to be taken, to occur or to be achieved, or the negative of these words or other variations thereof, have been used to identify this forward-looking information. Specific forward-looking statements include, without limitation, any disclosure regarding future results of operations, future results of transactions, economic conditions and planned action plans. Investors and other parties are advised that there is not necessarily a correlation between the number of SKUs manufactured and shipped and revenues and profits, and this information should not be relied on unduly.

Risks and uncertainties that may affect forward-looking statements include, but are not limited to, Canadian regulatory risk, Australian regulatory risk, US regulatory risk, bans on border crossings and travel to the United States, uncertainties, effects and responses to the COVID-19 pandemic, dependence on licenses, expansion of facilities, competition, dependence on the cannabis supply and dependence on other key inputs, dependence on with respect to senior management and key personnel, general business risks and liability, regulation of the cannabis industry, changing laws, regulations and guidelines, compliance with laws, business history, ” limited operations, vulnerability to rising energy costs, unfavorable consumer advertising or perception, product liability, Risks related to intellectual property, product recalls, difficulties with forecasting, growth management and litigation, many of which are beyond the control of The Société Valens. For a more complete discussion of the risks that The Valens Company faces, and which may cause The Valens Company’s actual financial results, performance or achievements to differ materially from the estimated future results, performance or achievements expressed or implied For forward-looking information or forward-looking statements, please refer to the latest annual information form of The Valens Company filed with the Canadian securities regulatory authorities at or on The Valens Company website at The risks described in this Annual Information Form are incorporated herein by reference. Although the forward-looking statements contained herein reflect management’s current beliefs and reasonable assumptions based on information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such information. prospective. Valens cautions you not to place undue reliance on these forward-looking statements. Valens disclaims any intention or obligation to update or revise any forward-looking statement whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as an offer to sell or a solicitation to buy or sell securities of The Valens Company.

Show original content to download multimedia:

SOURCE Valens Inc.

About William W.

Check Also

Clinical Trials Imaging Market Size and Outlook 2028 | Main companies – Navitas Life Sciences, IXICO, PLC, Radiant Sage, BioClinica, ICON Public Limited Company (Ireland), Medpace, Biomedical Systems, Cardiovascular Imaging Technologies, BioTelemetric,

New Jersey, United States, – A recent market research report added to the repository of …